Management of Eumycetoma

Tjokorde Istri Nyndia Vaniari, Sunarso Suyoso, Linda Astari, Yuri Widia, Sylvia Anggraeni, Evy Ervianti

= http://dx.doi.org/10.20473/bikk.V32.3.2020.232-238
Abstract views = 519 times | downloads = 146 times

Abstract


Background: Mycetoma is a chronic inflammatory disease of the skin that can extend to the fascia, tendons, muscles, and bones. Caused by a bacterium called actinomycetoma and a fungus called eumycetoma are responsible for mycetoma, both of which must be distinguished because they require different medical therapy. Eumycetoma is a localized disease, chronic, and growing slowly. Most of eumycetoma patients had delays in seeking medical care. Purpose: To provide an overview and discuss various aspects of eumycetoma, including its epidemiology, etiology, pathogenesis, classification, clinical picture, diagnosis, differential diagnosis, and therapy. Review: Eumycetoma infection begins as infectious agents enter through the skin with a minor trauma caused by objects contaminated with fungi, forming granular or granulomatous lesions with tract and sinus in there. The infection can spread from the site of inoculation into the muscles and bones. The diagnosis is based on anamnesis (chronic and painless), the triad of tumefaction, draining sinuses and grains, and laboratory investigation. It’s a difficult case, often recur and difficult to be surgical excisison, so that the best first option therapy is the combination of itraconazole and terbinafine itself as an alternative to surgical therapy at least 6 months. Conclusion: Eumycetoma is an infection caused by a fungus with granulomatous lesions with sinus formation and grains in it. The best first option therapy is the combination of itraconazole and terbinafine although it’s still an early case.


Keywords


eumycetoma; actinomycetoma; fungal infection; management;

Full Text:

PDF

References


Bravo FG, Arenas R, Sigall DA. Actinomycoses, nocardiosis, and actinomycetoma. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS. Editors. Fitzpatricks’s dermatology in general medicine. 9th ed. New York: Mc Graw-Hill; 2019. p. 2876-90.

Hay RJ. Deep fungal infections. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS. Editors. Fitzpatricks’s dermatology in general medicine. 9th ed. New York: Mc Graw-Hill; 2019. p. 2965-85.

Mohamed HT, Fahal A, Sande WWJ. Mycetoma: epidemiology, treatment challenges, and progress. Res Rep Trop Med 2015; 6:31-6.

Prasetyo AD, Suyoso S. Studi retrospektif kasus mikosis subkutis di Instalasi Rawat Inap Kesehatan Kulit dan Kelamin RSUD Dr. Soetomo Surabaya yang dirawat selama periode 1 Januari 2000 sampai dengan 31 Desember 2009. Berkala Ilmu Kesehatan Kulit dan Kelamin. Surabaya 2010; 23(1): 17-24.

Hinshaw MA, Longley BJ. Fungal Disease. In: Elder DE, Elenitsas R, Rosenbach M, Murphy GF, Rubin Ai, Xu X, editors. Lever’s Histophatology of the Skin. 11th ed. Philadelphia: Wolter Kluwer; 2015. p. 3961-65.

Widaty S. Obat Antijamur pada mikosis profunda. Dalam: Bramono K, Suyoso S, Widaty S, Ramali LM, Siswati AS, Ervianti E, editor. Mikosis profunda. Edisi pertama. Surabaya: Airlangga University Press; 2019. h.141-58.

Estrada R, Chavez-Lopez G, Estrada-Chavez G, Lopez-Martinez R, Welsh O. Eumycetoma. Clin Dermatol 2012; 30: 389-96.

Welsh O, Salinas-Carmona MC, Garza JAC, Rodriguez-Escamilla IM, Sanchez-Mezza E. Current treatment of mycetoma. Curr Treat Options Infect Dis 2018; 10: 389-96.

Brufman T, Ben-Ami R, Mizrahi M, Bash E, Paran Y. Mycetoma of the foot caused by Madurella mycetomatis in migrants from Sudan. IMAJ 2015; 17: 418–20.

Mhmoud NA, Ahmed SA, Fahal AH, Hoog GS, Ende AHG, Sande WWJ. Pleurostomophora ochracea, a novel agent of human eumycetoma with yellow grains. J Clin Microbiol 2012; 50(9): 2987–94.

Ali A, Khadda S, Yadav AK, Parmar A, Sakhrani JK, Kapoor A. Giant eumycetoma gluteal region: excision and V-Y flap advancement.Int J Sci Rep 2015; 1(2): 146-7.

Nenoff P, Sande WWJ, Fahal AH, Reinel D, Schöfer H. Eumycetoma and actinomycetoma: an update on causative agents, epidemiology, pathogenesis, diagnostics, and therapy. JEADV 2015; 29(10): 1873-83.

Kothiwala SK, Purohit S, Meena M, Jindal A. Black grain eumycetoma of the breast misdiagnosed as fibroadenoma. IJDVL 2015; 81(5): 521-3.

Nenoff P, Sande WWJ, Fahal AH, Reinel D, Schofer H. Eumycetoma and actinomycetoma–an update on causative agents, epidemiology, pathogenesis, diagnostics and therapy. J Eur Acad Dermatol Venereol 2015; 29:1873–83.

Estrada R, Chávez-López G, Estrada-Chávez G, López-Martínez R, Welsh O. Eumycetoma. J Clin Dermatol 2012; 30: 389-96.

Thilakavathy P, Vijaykumar GS, Janagond AB, Vithiya G, Yegumuthu K. A Case report of eumycetoma: emphasizing the need for early diagnosis and appropriate management. Sch J Med Case Rep 2015; 3(3): 225-7.

Sampaio FM, Galhardo MC, Quintella LP, Souza PR, Coelho JM, Valle AC. Mycetoma by Madurella mycetomatis with 30 years of evolution: a therapeutic challenge. An Bras Dermatol 2013; 88(6 Suppl 1): 82-4.

Herwanto N, Hidayati A N, Ervianti E, Suyoso S. Enterocutan and nephrocutan fistule : a rare complication of eumycetoma (freepaper presentation). The 6th Asia Pacific Society for Medical Mycology Congress. 2016, October 20-22; Bali; Indonesia

Belkum A, Fahal A, Sande WWJ. Mycetoma caused by Madurella mycetomatis: a completely neglected medico-social dilemma. In: N. Curtis, editor. Hot topics in infection and immunity in children. 9th. New York : Springer Science & Business Media; 2013. p.179-89.

Suyoso S, Bramono K, Widaty S, Ervianti E, and Astari L. Laboratory diagnose of subcutaneous mycoses (Workshop). The 23rd Regional Conference of Dermatology and the 16th Annual Scientific Meeting of the Indonesian Society of Dermatology and Venerology 2018, August 8-11; Surabaya, Indonesia.

Sakayama K, Kidani T, Sugawara Y, Fujibuchi T, Miyawaki J, Miyazaki T, Yamamoto H. Mycetoma of foot: a rare case report and review of the literature. Foot Ankle Int 2014; 25(1): 763-7.

Welsh O, Vera-Cabrera L, Welsh E, Salinas MC. Actinomycetoma and advance in its treatment. Clin Dermatol 2012; 30: 372-81.

Miranda E. Eumisetoma. Dalam Bramono K, Suyoso S, Widaty S, Ramali LM, Siswati AS, Ervianti E, editor. Mikosis Profunda edisi pertama, Surabaya; Airlangga University Press; 2019: 41-52.

Bramono K. Aktinomisetoma. Dalam Bramono K, Suyoso S, Widaty S, Ramali LM, Siswati AS, Ervianti E, editor. Mikosis Profunda edisi pertama. Surabaya; Airlangga University Press; 2019: 53-64.

Reis CMS, Reis-Filho EGM.Mycetomas: An epidemiological, etiological, clinical, laboratory, and therapeutic review. An Bras Dermatol 2018; 93(1): 08-18.

Welsh O, Al-Abdely HM, Salinas-Carmona MC, Fahal AH. Mycetoma medical therapy. PLoS Negl Trop Dis 2014; 8(10): 1-8.

Mhmoud NA, Fahal AH, Mahgoub ES, Sande WWJ. The combination of amoxicillin-clavulanic acid and ketoconazole in the treatment of Madurella mycetomatis eumycetoma and Staphylococcus aureus co-infection. PLoS Negl Trop Dis 2014; 8(6): 1-5.

Agarwal P, Agarwal US, Gupta R. Eumycetoma foot: successful treatment with combination of itraconazole and potassium iodide. Indian J Dermatol 2018; 1(2): 53-5.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Berkala Ilmu Kesehatan Kulit dan Kelamin

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

 

Lisensi Creative Commons
Creations are distributed below Lisensi Creative Commons Atribusi-NonKomersial 4.0 Internasional.

View My Stats